Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F6W8J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,540
Award facts
- Contract value 100% obligated
- $23,540.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a subsidiary of Cencora Inc., was awarded a delivery order valued at $23,540.45 by the Defense Logistics Agency (DLA) on January 12, 2026, for the supply of Dupixent 300 mg/2 ml pen injections. The contract is firm fixed-price with no set-aside designation, indicating competitive award, and is scheduled for completion by January 13, 2026. The place of performance is Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is located. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 vehicle through December 2026 that enables the company to supply comprehensive pharmaceutical products and medical supplies globally to support military healthcare programs.
AmerisourceBergen has established itself as a critical pharmaceutical distributor for federal medical procurement, particularly serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive contract history with DLA demonstrates its capability to efficiently deliver diverse pharmaceutical products across multiple therapeutic domains on a competitive basis. Dupixent (dupilumab) is a biologic medication used for treating atopic dermatitis, asthma, and other inflammatory conditions, representing the type of specialty pharmaceutical that the company routinely procures for military and veteran healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F6W8J?
SPE2DR26F6W8J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F6W8J worth?
The government has obligated $23,540 on SPE2DR26F6W8J.
Is contract SPE2DR26F6W8J an order under another contract?
Yes. SPE2DR26F6W8J is a delivery order under SPE2DR25D3013, an indefinite delivery contract.
Was contract SPE2DR26F6W8J competed?
The extent of competition for SPE2DR26F6W8J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award